Wealth Enhancement Advisory Services LLC Sells 500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Wealth Enhancement Advisory Services LLC reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,481 shares of the biotechnology company’s stock after selling 500 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Sarepta Therapeutics were worth $560,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Commonwealth Equity Services LLC increased its stake in Sarepta Therapeutics by 8.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after purchasing an additional 418 shares in the last quarter. PFG Advisors bought a new stake in shares of Sarepta Therapeutics during the first quarter worth $591,000. Oppenheimer Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics by 32.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 874 shares during the period. Swiss National Bank lifted its position in Sarepta Therapeutics by 6.3% in the 1st quarter. Swiss National Bank now owns 166,183 shares of the biotechnology company’s stock valued at $21,514,000 after acquiring an additional 9,900 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Sarepta Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 61,451 shares of the biotechnology company’s stock worth $7,956,000 after purchasing an additional 5,332 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity

In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SRPT shares. Citigroup dropped their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Guggenheim boosted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday. Raymond James reaffirmed an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. Finally, UBS Group increased their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $181.33.

Sarepta Therapeutics Stock Performance

SRPT opened at $120.42 on Friday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The stock has a market cap of $11.48 billion, a price-to-earnings ratio of 267.61 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12-month low of $75.85 and a 12-month high of $173.25. The business has a 50 day moving average of $126.20 and a 200-day moving average of $132.77.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the firm posted ($0.27) EPS. The company’s quarterly revenue was up 38.9% on a year-over-year basis. On average, equities research analysts expect that Sarepta Therapeutics, Inc. will post 1.48 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.